Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 1Phase 1 1

Status

Completed 3Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Lymphoid 4

Conditions

Lymphoma 27Lymphoma, Non-Hodgkin 24Leukemia, Lymphocytic, Chronic, B-Cell 24Lymphoma, Mantle-Cell 23Lymphoma, Follicular 17Lymphoma, Large B-Cell, Diffuse 15Multiple Myeloma 14Recurrence 13Hodgkin Disease 12Lymphoma, B-Cell, Marginal Zone 7Leukemia 7Waldenstrom Macroglobulinemia 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Neoplasms, Plasma Cell 4Neoplasms 4Leukemia, B-Cell 4Hematologic Neoplasms 4Myeloproliferative Disorders 3Myelodysplastic Syndromes 3Lymphoma, T-Cell, Peripheral 3Lymphoma, T-Cell 3Lymphoma, B-Cell 3Leukemia, Myeloid, Acute 3Leukemia, Lymphoid 3Small Cell Lung Carcinoma 2Leukemia, Biphenotypic, Acute 2Burkitt Lymphoma 2Sezary Syndrome 1Sarcoma 1Renal Insufficiency, Chronic 1

Interventions

Cyclophosphamide 9ofatumumab 8fludarabine 5Rituximab 5fludarabine phosphate 4Bendamustine Hydrochloride 4venetoclax 3ibrutinib 3acalabrutinib 3Melphalan 3obinutuzumab 2Whole-Body Irradiation 2Vincristine 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Lenalidomide 2Immunotherapy, Adoptive 2Busulfan 2Bortezomib 2Alemtuzumab 2zanubrutinib 1thymoglobulin 1tenofovir alafenamide 1pomalidomide 1pivalyloxymethyl butyrate 1pirtobrutinib 1pegaspargase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × Leukemia, B-Cell × Bendamustine Hydrochloride × Clear all
NCT04515238 2025-06-10

CLL2-BZAG

German CLL Study Group

Phase 2 Active not recruiting
42 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT03787264 2024-12-30

CLL2-BAAG

German CLL Study Group

Phase 2 Completed
46 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell

NCT02689141 2020-06-11

Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)

German CLL Study Group

Phase 2 Completed
66 enrolled
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT01520922 2017-01-19

Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Novartis

Phase 2 Completed
99 enrolled 27 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Neoplasms, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡